The pulmonary, critical care, and sleep communities have made progress toward evidence-based care and developing novel therapies for "incurable" diseases. However, recent data challenge current approaches and create uncertainty about the research and management approaches to highly burdensome respiratory conditions. These controversies include 1) management of severe asthma, 2) apnea-hypopnea index as a prognostic marker in OSA, 3) correcting cellular aging in fibrotic and inflammatory diseases, and 4) targeting oxygenation during ventilation of acute respiratory distress syndrome. This session will address the state of the science and evidence for aspects of managing these conditions to inform clinical decision-making and future research.
• Inform the clinicians and researchers about specific areas of debate in management of common and burdensome respiratory conditions: 1) Asthma; 2) OSA; 3) Fibrotic lung disease and 4) ARDS
• Apply state of the science to help the audience decide on appropriate 1) management of severe Asthma with biologics; 2) use of the AHI in OSA patients; 3) therapeutics in lung fibrosis and 4) treatment of ARDS for their patients
• Identify key gaps for conditions mentioned in objectives 1 and 2 that should inform future research
Michael Wechsler, MD, MSc
Monica Kraft, MD, ATSF
Praveen Akuthota, MD, ATSF
Michael Wechsler, MD, MSc
Neomi Shah, MD, MPH, MSci
Atul Malhotra, MD, ATSF
Susan Redline, MD, MPH
Andrey Zinchuk, MD, MHS, BS
Mauricio Rojas, MD
Anoop Nambiar, MD, MSCR
Bruno Crestani, MD, PhD
Mauricio Rojas, MD
Annette Esper, MD, MS, ATSF
Sarina Sahetya, MD, MHS
Jeremy Beitler, MD, MPH
Annette Esper, MD, MS, ATSF
Introduction to Debate 1: Biologics Overlap in Asthma
Truth: Biologics Can Be Combined and Overlapped in Severe Asthma
Myth: Biologics Can Be Combined and Overlapped in Severe Asthma
Summary and Audio Response Results, Debate 1
Introduction to Debate 2: Utility of the AHI
Truth: The AHI Should Be Used in Prognostication and Treatment of OSA
Myth: The AHI Should Be Used in Prognostication and Treatment of OSA
Summary and Audio Response Results (Debate 2)
Introduction to Debate 3: Senolytics in Respiratory Diseases
Truth: Senolytics Can Be Effective in Fibroproliferative and Other Respiratory Diseases
Myth: Senolytics Can Be Effective in Fibroproliferative and Other Respiratory Diseases
Summary and Audio Response Results (Debate 3)
Introduction to Debate 4: PEEP and Oxygenation in ARDS
Truth: PEEP Titration in ARDS Should Prioritize Arterial Oxygenation
Myth: PEEP Titration in ARDS Should Prioritize Arterial OxygenationSummary and Audio Response Results (Debate 4 & Overall session)